SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Several antidiabetic therapies have been investigated in the treatment of MASLD with varying results including metformin [6], glucagon-like peptide‐1 receptor agonists (GLP- 1RAs), and Sodium-glucose co-transporter type 2 (SGLT2) inhibitors [7].